Kymera Therapeutics (KYMR) Bank of America Global Healthcare Conference 2026 summary

Strategic and operational overview

• Celebrated 10-year anniversary, reflecting on achievements and future opportunities in targeted protein degradation, with six programs advanced to the clinic and a focus on immunology.

• Intends to introduce at least one new program annually, with current emphasis on phase II studies for KT-621 in atopic dermatitis (AD) and asthma.

• Expects to complete the AD trial this year and asthma next year, with data for both anticipated in 2027.

• Ongoing partnerships with Gilead and Sanofi continue to progress alongside internal programs.

• Pediatric populations and early intervention are highlighted as future strategic priorities.

Clinical development and differentiation

• KT-621, a STAT6 degrader, is positioned as an oral alternative to injectable biologics, aiming for consistent and deep pathway inhibition.

• Phase IIb BROADEN2 study in AD is a dose-ranging, placebo-controlled trial, with primary endpoint as percent change in EASI at 16 weeks; results will inform phase III dose selection.

• Asthma phase IIb (BREADTH) study is ongoing, with endpoints tailored to respiratory outcomes; both studies use three dose levels versus placebo.

• Early data suggest efficacy and safety comparable to DUPIXENT, with a focus on patients not currently on systemic therapies.

• Safety monitoring includes conjunctivitis and viral infections, with no major concerns observed in early studies.

Market positioning and future outlook

• Large market opportunities identified in both AD and asthma, with significant untreated populations and potential for pediatric expansion.

• Oral administration is expected to appeal to patients averse to injections and may facilitate earlier line use, especially before biosimilar competition emerges.

• Business development remains focused on internal execution, with openness to partnerships or in-licensing if strategically advantageous.

• Resource allocation and development group expansion are planned to support multiple phase III trials and potential parallel indication development.

• IRF5 program targets autoimmune diseases like lupus and IBD, with preclinical data showing strong efficacy and plans for a phase I healthy volunteer study, with data expected in the second half of the year.